The improved expansion of CD8+ T cells, together with the improved preservation of CD28 expression, antigen recall responses, and enhanced anti-tumor effector functions when an agonistic anti-4-1BB was added early in the REP process indicate that a lack of adequate 4-1BB co-stimulation in the current TIL REP protocols is indeed a critical issue. The gene discussed is CD28; the disease is neoplasm.